Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages 601-607

  Sugita, Chihiro ^a   Yamashita, Atsushi ^a   Moriguchi Goto, Sayaka ^a   Furukoji, Eiji ^a   Takahashi, Misaki ^a   Harada, Aya ^b   Soeda, Tetsuhiro ^b   Kitazawa, Takehisa ^b   Hattori, Kunihiro ^b   Tamura, Shozo ^a   Asada, Yujiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Deep venous thrombosis; Factor VIII; Fibrin; Platelet; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; COLLAGEN TYPE 3; FIBRIN; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN G1; PROTHROMBIN; THROMBIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ERYTHROCYTE; FEMALE; FIBRIN CLOT; HUMAN; IMMOBILIZATION; IMMUNOHISTOCHEMISTRY; LIGHT CHAIN; MALE; MOLECULAR RECOGNITION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTHROMBIN TIME; SHEAR STRESS; SURFACE PROPERTY; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VENOUS BLOOD;

ADULT; AGED; ANIMALS; BLOOD PLATELETS; COLLAGEN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FACTOR VIII; FEMALE; FIBRIN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED MRL LPR; MIDDLE AGED; PLATELET AGGREGATION; SHEAR STRENGTH; THROMBIN; VENOUS THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 70349847228     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.035     Document Type: Article

References (37)

1. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998) 585-593
2. Hirsh J., and O'Donnell M.J. Venous thromboembolism after long flights: are airlines to blame?. Lancet 357 (2001) 1461-1462
3. Heit J.A. Mapping out the future in venous thromboembolism and acute coronary syndromes. Semin Thromb Hemost 28 (2002) 33-39
4. Koster T., Rosendaal F.R., de Ronde H., Briët E., Vandenbroucke J.P., and Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342 (1993) 1503-1506
5. Lenting P.J., van Mourik J.A., and Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 92 (1998) 3983-3996
6. Lollar P., Hill-Eubanks D.C., and Parker C.G. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263 (1988) 10451-10455
7. Duffy E.J., Parker E.T., Mutucumarana V.P., Johnson A.E., and Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem 267 (1992) 17006-17011
8. Ovanesov M.V., Lopatina E.G., Saenko E.L., Ananyeva N.M., Ul'yanova L.I., Plyushch O.P., et al. Effect of factor VIII on tissue factor-initiated spatial clot growth. Thromb Haemost 89 (2003) 235-242
9. Koster T., Blann A.D., Briët E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
10. Martinelli I. Von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42 (2005) 49-55
11. Tirado I., Mateo J., Soria J.M., Oliver A., Martínez-Sánchez E., Vallvé C., et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 93 (2005) 468-474
12. Kraaijenhagen R.A., in't Anker P.S., Koopman M.M., Reitsma P.H., Prins M.H., van den Ende A., et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 83 (2000) 5-9
13. Dewerchin M., Van der Elst L., Singh I., Grailly S., Saint-Remy J.M., Collen D., et al. Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice. J Thromb Haemost 2 (2004) 77-84
14. Chauhan A.K., Kisucka J., Lamb C.B., Bergmeier W., and Wagner D.D. Von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 109 (2007) 2424-2429
15. Moriguchi-Goto S., Yamashita A., Tamura N., Soejima K., Takahashi M., Nakagaki T., et al. ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions. Atherosclerosis 203 (2009) 409-416
16. Yamashita A., Nishihira K., Kitazawa T., Yoshihashi K., Soeda T., Esaki K., et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost 4 (2006) 1496-1501
17. van Dieijen G., Tans G., Rosing J., and Hemker H.C. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 256 (1981) 3433-3442
18. Eaton D., Rodriguez H., and Vehar G.A. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 25 (1986) 505-512
19. Ruggeri Z.M., and Savage B. Platelet-vessel wall interactions in flowing blood. In: Colman R.W., Marder V.J., Clowes A.W., George J.N., and Goldhaber S.Z. (Eds). Hemostasis and Thrombosis Basic principles and clinical practice (2006), Lippincott Williams & Wilkins, Philadelphia 723-735
20. Gatt A., van Veen J.J., Bowyer A., Woolley A.M., Cooper P., Kitchen S., et al. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. Br J Haematol 142 (2008) 946-952
21. Stein P.D., and Evans H. An autopsy study of leg vein thrombosis. Circulation 35 (1967) 671-681
22. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355 (2000) 1295-1302
23. Hovens M.M.C., Snoep J.D., Tamsma J.T., and Huisman M.V. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 4 (2006) 1470-1475
24. Nesheim M., Pittman D.D., Giles A.R., Fass D.N., Wang J.H., Slonosky D., et al. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 266 (1991) 17815-17820
25. Koedam J.A., Meijers J.C., Sixma J.J., and Bouma B.N. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 82 (1988) 1236-1243
26. Hill-Eubanks D.C., and Lollar P. Von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 265 (1990) 17854-17858
27. Monroe D.M., Hoffman M., and Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 (2002) 1381-1389
28. Ovanesov M.V., Ananyeva N.M., Panteleev M.A., Ataullakhanov F.I., and Saenko E.L. Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate. J Thromb Haemost 3 (2005) 321-331
29. Panteleev M.A., Ovanesov M.V., Kireev D.A., Shibeko A.M., Sinauridze E.I., Ananyeva N.M., et al. Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 90 (2006) 1489-1500
30. Goodnough L.T., Saito H., and Ratnoff O.D. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 62 (1983) 248-255
31. Kasper C.K. Postoperative thromboses in hemophilia B. N Engl J Med 289 (1973) 160
32. Franchini M. Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 92 (2004) 298-304
33. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., and Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
34. Aledort L.M. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 14 (2008) 39-43
35. Schambeck C.M., Grossmann R., Zonnur S., Berger M., Teuchert K., Spahn A., et al. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 92 (2004) 42-46
36. Wilcox J.N., Smith K.M., Schwartz S.M., and Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86 (1989) 2839-2843
37. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis 36 (2006) 104-107